ArticleInfectious medicine2026
Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for adults in China.
Article in Infectious medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With population aging and the rising burden of chronic diseases, pneumococcal disease imposes increasing pressure on the healthcare system in China. This study evaluated the cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged 50 years. Methods: A decision-tree-based static cohort Markov model was developed to estimate lifetime costs and health outcomes from a societal perspective under a hypothetical strategy of PPSV23 vaccination at age 50 with revaccination at age 65 to assess long-term protection under waning immunity; a single-dose strategy was examined in scenario analyses. The model estimated quality-adjusted life-years, life-years, incremental cost-effectiveness ratios, and cases and deaths averted. Deterministic and probabilistic sensitivity analyses were conducted to assess parameter uncertainty. Price simulations were performed across different willingness-to-pay thresholds. Safety was evaluated using the Vaccine Adverse Event Reporting System through descriptive analysis and empirical Bayesian data mining. Results: The estimated incremental cost-effectiveness ratios for PPSV23 compared to no vaccination are $12,937.07 per quality-adjusted life-year gained and $9,622.25 per life-year gained, with the administration of PPSV23 preventing 1,115 cases and 35 deaths from a study population of 100,000 individuals. The greatest sensitivity was observed to variations in the discount rate, serotype coverage of PPSV23, vaccine efficacy of PPSV23 and cost per dose of PPSV23. No new or unexpected safety concerns for PPSV23 were identified. Conclusions: PPSV23 is a cost-effective option for adults aged 50 years in China at higher willingness-to-pay thresholds (e.g., 2-3 × the gross domestic product per capita), with a favorable post-marketing safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.